The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
Matrix Metalloproteinases As Novel Biomarker s and Potential Therapeutic Targets in Human Cancer
Open accessAbstract
The matrix metalloproteinase (MMP) family of enzymes is comprised of critically important extracellular matrix remodeling proteases whose activity has been implicated in a number of key normal and pathologic processes. The latter include tumor growth, progression, and metastasis as well as the dysregulated angiogenesis that is associated with these events. As a result, these proteases have come to represent important therapeutic and diagnostic targets for the treatment and detection of human cancers. In this review, we summarize the literature that establishes these enzymes as important clinical targets, discuss the complexity surrounding their choice as such, and chronicle the development strategies and outcomes of their clinical testing to date. The status of the MMP inhibitors currently in US Food and Drug Administration approved clinical trials is presented and reviewed. We also discuss the more recent and successful targeting of this enzyme family as diagnostic and prognostic predictors of human cancer, its status, and its stage. This analysis includes a wide variety of human cancers and a number of human sample types including tissue, plasma, serum, and urine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc822 · Cited by 6,628
Structure and function of matrix metalloproteinases and TIMPs
NAGASE, H., VISSE, R., & MURPHY, G. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.12.002 · Cited by 3,409
A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., et al. (1997) · Nature · doi:10.1038/385729a0 · Cited by 3,149
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
Matrix metalloproteinases as modulators of inflammation and innate immunity
Parks, W. C., Wilson, C. L., & López-Boado, Y. S. (2004) · Nature Reviews Immunology · doi:10.1038/nri1418 · Cited by 1,929
MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis
Coussens, L. M., Tinkle, C. L., Hanahan, D., & Werb, Z. (2000) · Cell · doi:10.1016/s0092-8674(00)00139-2 · Cited by 1,306
Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability
Radisky, D. C., Levy, D. D., Littlepage, L. E., Liu, H., Nelson, C. M., Fata, J. E., Leake, D., Godden, E. L., Albertson, D. G., Angela Nieto, M., et al. (2005) · Nature · doi:10.1038/nature03688 · Cited by 1,284
Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
Overall, C. M., & Kleifeld, O. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1821 · Cited by 1,214
EDWARDS, D., HANDSLEY, M., & PENNINGTON, C. (2008) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.08.001 · Cited by 1,161
Houck, K. A., Leung, D. W., Rowland, A. M., Winer, J., & Ferrara, N. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35712-0 · Cited by 1,127
ADAMs: key components in EGFR signalling and development
Blobel, C. P. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1548 · Cited by 1,090
Proteolytic remodeling of extracellular matrix
Birkedal-Hansen, H. (1995) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(95)80116-2 · Cited by 1,074
Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice
Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., & Hanahan, D. (1999) · Science · doi:10.1126/science.284.5415.808 · Cited by 988
Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands
Sahin, U., Weskamp, G., Kelly, K., Zhou, H.-M., Higashiyama, S., Peschon, J., Hartmann, D., Saftig, P., & Blobel, C. P. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200307137 · Cited by 979
Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy
Hidalgo, M., & Eckhardt, S. G. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.3.178 · Cited by 798
Tetracyclines: Nonantibiotic properties and their clinical implications
Sapadin, A. N., & Fleischmajer, R. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.10.004 · Cited by 768
Progress in matrix metalloproteinase research
MURPHY, G., & NAGASE, H. (2008) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.05.002 · Cited by 759
In vivo molecular target assessment of matrix metalloproteinase inhibition
Bremer, C., Tung, C.-H., & Weissleder, R. (2001) · Nature Medicine · doi:10.1038/89126 · Cited by 726
Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1
Noë, V., Fingleton, B., Jacobs, K., Crawford, H. C., Vermeulen, S., Steelant, W., Bruyneel, E., Matrisian, L. M., & Mareel, M. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.1.111 · Cited by 695
Maretzky, T., Reiss, K., Ludwig, A., Buchholz, J., Scholz, F., Proksch, E., de Strooper, B., Hartmann, D., & Saftig, P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500918102 · Cited by 673
Lochter, A., Galosy, S., Muschler, J., Freedman, N., Werb, Z., & Bissell, M. J. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.139.7.1861 · Cited by 655
Role of Cell Surface Metalloprotease Mt1-Mmp in Epithelial Cell Migration over Laminin-5
Koshikawa, N., Giannelli, G., Cirulli, V., Miyazaki, K., & Quaranta, V. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.148.3.615 · Cited by 655
Whitelock, J. M., Murdoch, A. D., Iozzo, R. V., & Underwood, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.17.10079 · Cited by 597
Loss of collagenase-2 confers increased skin tumor susceptibility to male mice
Balbín, M., Fueyo, A., Tester, A. M., Pendás, A. M., Pitiot, A. S., Astudillo, A., Overall, C. M., Shapiro, S. D., & López-Otín, C. (2003) · Nature Genetics · doi:10.1038/ng1249 · Cited by 536
Unemori, E. N., Ferrara, N., Bauer, E. A., & Amento, E. P. (1992) · Journal of Cellular Physiology · doi:10.1002/jcp.1041530317 · Cited by 526
Dong, Z., Kumar, R., Yang, X., & Fidler, I. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81926-1 · Cited by 525
Golub, L. M., Ramamurthy, N. S., McNamara, T. F., Greenwald, R. A., & Rifkin, B. R. (1991) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/10454411910020030201 · Cited by 522
TIMP-2 Mediated Inhibition of Angiogenesis
Seo, D.-W., Li, H., Guedez, L., Wingfield, P. T., Diaz, T., Salloum, R., Wei, B.-Y., & Stetler-Stevenson, W. G. (2003) · Cell · doi:10.1016/s0092-8674(03)00551-8 · Cited by 508
Stetler-Stevenson, W. G. (2008) · Science Signaling · doi:10.1126/scisignal.127re6 · Cited by 489
Xu, J., Rodriguez, D., Petitclerc, E., Kim, J. J., Hangai, M., Yuen, S. M., Davis, G. E., & Brooks, P. C. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200103111 · Cited by 489
Activity-based probes for the proteomic profiling of metalloproteases
Saghatelian, A., Jessani, N., Joseph, A., Humphrey, M., & Cravatt, B. F. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402784101 · Cited by 456
The ADAMs: signalling scissors in the tumour microenvironment
Murphy, G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2459 · Cited by 451
Matrix Metalloproteinases Generate Angiostatin: Effects on Neovascularization
Cornelius, L. A., Nehring, L. C., Harding, E., Bolanowski, M., Welgus, H. G., Kobayashi, D. K., Pierce, R. A., & Shapiro, S. D. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.12.6845 · Cited by 444
Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead
van Hinsbergh, V. W. M., & Koolwijk, P. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvm102 · Cited by 420
Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model
Fang, J., Shing, Y., Wiederschain, D., Yan, L., Butterfield, C., Jackson, G., Harper, J., Tamvakopoulos, G., & Moses, M. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.8.3884 · Cited by 393
Self-citationGeneration and degradation of human endostatin proteins by various proteinases
Ferreras, M., Felbor, U., Lenhard, T., Olsen, B. R., & Delaissé, J.-M. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02249-3 · Cited by 377
Haro, H., Crawford, H. C., Fingleton, B., Shinomiya, K., Spengler, D. M., & Matrisian, L. M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci7091 · Cited by 364
Fowlkes, J. L., Enghild, J. J., Suzuki, K., & Nagase, H. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47310-3 · Cited by 347
Schmalfeldt, B., Prechtel, D., Härting, K., Späthe, K., Rutke, S., Konik, E., Fridman, R., Berger, U., Schmitt, M., Kuhn, W. C., et al. (2001) · PubMed · Cited by 334
Suzuki, M., Raab, G., Moses, M. A., Fernandez, C. A., & Klagsbrun, M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31730 · Cited by 330
Self-citationThe generation of endostatin is mediated by elastase.
Wen, W. X., Moses, M. A., Wiederschain, D., Arbiser, J. L., & Folkman, J. (1999) · PubMed · Cited by 318
Self-citationFernández, C. A., Yan, L., Louis, G., Yang, J., Kutok, J. L., & Moses, M. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2391 · Cited by 283
Self-citationMMPs as therapeutic targets—Still a viable option?
FINGLETON, B. (2008) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2007.06.006 · Cited by 279
Lamoreaux, W. J., Fitzgerald, M. E. C., Reiner, A., Hasty, K. A., & Charles, S. T. (1998) · Microvascular Research · doi:10.1006/mvre.1997.2056 · Cited by 278
O'Reilly, M. S., Wiederschain, D., Stetler-Stevenson, W. G., Folkman, J., & Moses, M. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.41.29568 · Cited by 272
Self-citationIncreased incidence of matrix metalloproteinases in urine of cancer patients.
Moses, M. A., Wiederschain, D., Loughlin, K. R., Zurakowski, D., Lamb, C. C., & Freeman, M. R. (1998) · PubMed · Cited by 272
Self-citationPrognostic significance of MMP‐9 and TIMP‐1 serum and tissue expression in breast cancer
Wu, Z., Wu, Q., Yang, J., Wang, H., Ding, X., Yang, F., & Xu, X. (2008) · International Journal of Cancer · doi:10.1002/ijc.23337 · Cited by 268
Self-citationApte, S. S. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.01.014 · Cited by 261
Targeting TACE-dependent EGFR ligand shedding in breast cancer
Kenny, P. A., & Bissell, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29518 · Cited by 252
ADAM 12 Cleaves Extracellular Matrix Proteins and Correlates with Cancer Status and Stage
Roy, R., Wewer, U. M., Zurakowski, D., Pories, S. E., & Moses, M. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409565200 · Cited by 244
Self-citationMatrix metalloproteinases at cancer tumor–host interface
NOEL, A., JOST, M., & MAQUOI, E. (2008) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2007.05.011 · Cited by 239
ZUCKER, S., HYMOWITZ, M., CONNER, C., ZARRABI, H. M., HUREWITZ, A. N., MATRISIAN, L., BOYD, D., NICOLSON, G., & MONTANA, S. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07687.x · Cited by 236
Chandler, S., Cossins, J., Lury, J., & Wells, G. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1677 · Cited by 226
HB-EGF Is a Potent Inducer of Tumor Growth and Angiogenesis
Ongusaha, P. P., Kwak, J. C., Zwible, A. J., Macip, S., Higashiyama, S., Taniguchi, N., Fang, L., & Lee, S. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0925 · Cited by 219
Tian, M., Cui, Y.-Z., Song, G.-H., Zong, M.-J., Zhou, X.-Y., Chen, Y., & Han, J.-X. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-241 · Cited by 214
Mañes, S., Mira, E., Barbacid, M. D. M., Ciprés, A., Fernández-Resa, P., Buesa, J. M., Mérida, I., Aracil, M., Márquez, G., & Martı́nez-A, C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.25706 · Cited by 210
Jones, L. E., Humphreys, M. J., Campbell, F., Neoptolemos, J. P., & Boyd, M. T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1157-03 · Cited by 200
Riddick, A. C. P., Shukla, C. J., Pennington, C. J., Bass, R., Nuttall, R. K., Hogan, A., Sethia, K. K., Ellis, V, Collins, A. T., Maitland, N. J., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602630 · Cited by 198
Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo
Sawaya, R. E., Yamamoto, M., Gokaslan, Z. L., Wang, S. W., Mohanam, S., Fuller, G. N., McCutcheon, I. E., Stetler-Stevenson, W. G., Nicolson, G. L., & Rao, J. S. (1996) · Clinical & Experimental Metastasis · doi:10.1007/bf00157684 · Cited by 197
Potent and Selective Mechanism-Based Inhibition of Gelatinases
Brown, S., Bernardo, M. M., Li, Z.-H., Kotra, L. P., Tanaka, Y., Fridman, R., & Mobashery, S. (2000) · Journal of the American Chemical Society · doi:10.1021/ja001461n · Cited by 197
Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera
Rocca, G. L., Pucci-Minafra, I., Marrazzo, A., Taormina, P., & Minafra, S. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601725 · Cited by 197
Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
Choe, G., Park, J. K., Jouben-Steele, L., Kremen, T. J., Liau, L. M., Vinters, H. V., Cloughesy, T. F., & Mischel, P. S. (2002) · PubMed · Cited by 197
Making the cut: Protease-mediated regulation of angiogenesis
ROY, R., ZHANG, B., & MOSES, M. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.022 · Cited by 193
Self-citationMorgia, G., Falsaperla, M., Malaponte, G., Madonia, M., Indelicato, M., Travali, S., & Mazzarino, M. C. (2005) · Urological Research · doi:10.1007/s00240-004-0440-8 · Cited by 190
Urinary Biomarkers Predict Brain Tumor Presence and Response to Therapy
Smith, E. R., Zurakowski, D., Saad, A., Scott, R. M., & Moses, M. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1253 · Cited by 182
Self-citationChemically modified tetracyclines as inhibitors of matrix metalloproteinases
Acharya, M. R., Venitz, J., Figg, W. D., & Sparreboom, A. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.04.002 · Cited by 175
Poola, I., DeWitty, R. L., Marshalleck, J. J., Bhatnagar, R., Abraham, J., & Leffall, L. D. (2005) · Nature Medicine · doi:10.1038/nm1243 · Cited by 174
The Clinical Relevance of Stromal Matrix Metalloproteinase Expression in Ovarian Cancer
Kamat, A. A., Fletcher, M., Gruman, L. M., Mueller, P., Lopez, A., Landen, C. N., Han, L., Gershenson, D. M., & Sood, A. K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2338 · Cited by 170
Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas
Rao, J. S., Yamamoto, M., Mohaman, S., Gokaslan, Z. L., Fuller, G. N., Stetler-Stevenson, W. G., Rao, V. H., Liotta, L. A., Nicolson, G. L., & Sawaya, R. E. (1996) · Clinical & Experimental Metastasis · doi:10.1007/bf00157681 · Cited by 169
Schäfer, B., Marg, B., Gschwind, A., & Ullrich, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400129200 · Cited by 168
Illman, S. A., Lehti, K., Keski-Oja, J., & Lohi, J. (2006) · Journal of Cell Science · doi:10.1242/jcs.03157 · Cited by 168
Low-Molecular-Weight Heparin in Patients With Advanced Cancer: A Phase 3 Clinical Trial
Sideras, K., Schaefer, P. L., Okuno, S. H., Sloan, J. A., Kutteh, L., Fitch, T. R., Dakhil, S. R., Levitt, R., Alberts, S. R., Morton, R. F., et al. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.6.758 · Cited by 163
Thrailkill, K. M., Quarles, L. D., Nagase, H., Suzuki, K., SERRA, D. M., & Fowlkes, J. L. (1995) · Endocrinology · doi:10.1210/en.136.8.3527 · Cited by 163
Stone, A. L., Kröger, M., & Sang, Q. A. (1999) · Journal of Protein Chemistry · doi:10.1023/a:1020692710029 · Cited by 161
Zhang, B., Cao, X., Liu, Y., Cao, W., Zhang, F., Zhang, S., Li, H., Ning, L., Fu, L., Niu, Y., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-83 · Cited by 161
A Protective Role for Matrix Metalloproteinase-3 in Squamous Cell Carcinoma
McCawley, L. J., Crawford, H. C., King, L. E., Mudgett, J. S., & Matrisian, L. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0910 · Cited by 161
Grützmann, R., Lüttges, J., Sipos, B., Ammerpohl, O., Dobrowolski, F., Alldinger, I., Kersting, S., Ockert, D., Koch, R., Kalthoff, H., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601645 · Cited by 160
Tanaka, Y., Miyamoto, S., Suzuki, S. O., Oki, E., Yagi, H., Sonoda, K., Yamazaki, A., Mizushima, H., Maehara, Y., Mekada, E., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1426 · Cited by 158
Fridman, J. S., Caulder, E., Hansbury, M., Liu, X., Yang, G., Wang, Q., Lo, Y. Y. C., Zhou, B. S., Pan, M., Thomas, S. M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2116 · Cited by 157
Roy, R., Louis, G. W., Loughlin, K. R., Wiederschain, D., Kilroy, S. M., Lamb, C. C., Zurakowski, D., & Moses, M. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1136 · Cited by 157
Self-citationRatnikov, B. I., Rozanov, D. V., Postnova, T. I., Baciu, P. G., Zhang, H., DiScipio, R. G., Chestukhina, G. G., Smith, J. W., Deryugina, E. I., & Strongin, A. Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109580200 · Cited by 152
The Role of Tissue Inhibitors of Metalloproteinases in Tumorigenesis and Metastasis
Cruz‐Muñoz, W., & Khokha, R. (2008) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360801973244 · Cited by 150
The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis
Têtu, B., Brisson, J., Wang, C. S., Lapointe, H., Beaudry, G., Blanchette, C., & Trudel, D. (2006) · Breast Cancer Research · doi:10.1186/bcr1503 · Cited by 146
Matrix Metalloproteinase 1 (MMP1) Is Associated with Early-Onset Lung Cancer
Sauter, W., Rosenberger, A., Beckmann, L., Kropp, S., Mittelstraß, K., Timofeeva, M. N., Wölke, G., Steinwachs, A., Scheiner, D., Meese, E. U., et al. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-2840 · Cited by 144
Hilska, M., Roberts, P., Collan, Y. U., Laine, V. J. O., Kössi, J. A. O., Hirsimäki, P., Rahkonen, O. P., & Laato, M. K. (2007) · International Journal of Cancer · doi:10.1002/ijc.22747 · Cited by 143
ADAM-17 Expression in Breast Cancer Correlates with Variables of Tumor Progression
McGowan, P. M., Ryan, B. M., Hill, A. D. K., McDermott, E. W. M., O’Higgins, N. J., & Duffy, M. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2092 · Cited by 142
Molecular Profiling of ADAM12 in Human Bladder Cancer
Fröhlich, C., Albrechtsen, R., Dyrskjøt, L., Rudkjær, L. C. B., Orntoft, T. F., & Wewer, U. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1066 · Cited by 135
Liu, D., Nakano, J., Ishikawa, S., Yokomise, H., Ueno, M., Kadota, K., Urushihara, M., & Huang, C. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.07.005 · Cited by 131
Antimetastatic Activity of a Novel Mechanism-Based Gelatinase Inhibitor
Krüger, A., Arlt, M., Gerg, M., Kopitz, C., Bernardo, M. M., Chang, M., Mobashery, S., & Fridman, R. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3570 · Cited by 127
Ranuncolo, S. M., Armanasco, E., Cresta, C., Joffé, E. B. D. K., & Puricelli, L. (2003) · International Journal of Cancer · doi:10.1002/ijc.11288 · Cited by 127
Therapeutic Benefits from Targeting of ADAM Family Members
Moss, M. L., & Bartsch, J. W. (2004) · Biochemistry · doi:10.1021/bi049677f · Cited by 125
Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer
Leeman, M. F., McKay, J., & Murray, G. I. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.10.758 · Cited by 117
Witty, J. P., Lempka, T., Coffey, R. J., & Matrisian, L. M. (1995) · PubMed · Cited by 117
Maurel, J., Nadal, C., García‐Albéniz, X., Gallego, R., Carcereny, E., Almendro, V., Mármol, M., Gallardo, E., Auge, J. M., Longarón, R., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22799 · Cited by 113
Fernández, C. A., Butterfield, C., Jackson, G., & Moses, M. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306176200 · Cited by 110
Self-citationChen, J., Nelson, F. C., Levin, J. I., Mobilio, D., Moy, F. J., Nilakantan, R., Zask, A., & Powers, R. (2000) · Journal of the American Chemical Society · doi:10.1021/ja001547g · Cited by 108
Yang, W., Arii, S., Gorrín-Rivas, M. J., Mori, A. S., Onodera, H., & Imamura, M. (2001) · Cancer · doi:10.1002/1097-0142(20010401)91:7<1277::aid-cncr1129>3.0.co;2-h · Cited by 107
Loprinzi, C. L., Levitt, R., Barton, D. L., Sloan, J. A., Atherton, P., Smith, D. J., Dakhil, S. R., Moore, D. F., Krook, J. E., Rowland, K. M., et al. (2005) · Cancer · doi:10.1002/cncr.21107 · Cited by 101
Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications
Harper, J. W., & Moses, M. A. (2006) · Birkhäuser Basel eBooks · doi:10.1007/3-7643-7378-4_10 · Cited by 96
Self-citationADAM-17 predicts adverse outcome in patients with breast cancer
McGowan, P. M., McKiernan, E., Bolster, F., Ryan, B. M., Hill, A. D. K., McDermott, E. W. M., Evoy, D., O’Higgins, N. J., Crown, J. P., & Duffy, M. J. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm609 · Cited by 95
Urinary Metalloproteinases: Noninvasive Biomarkers for Breast Cancer Risk Assessment
Pories, S. E., Zurakowski, D., Roy, R., Lamb, C. C., Raza, S., Exarhopoulos, A., Scheib, R. G., Schumer, S., Lenahan, C., Borges, V. F., et al. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0365 · Cited by 95
Self-citationPlasma storage at −80 °C does not protect matrix metalloproteinase-9 from degradation
Rouy, D., Ernens, I., Jeanty, C., & Wagner, D. R. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.10.052 · Cited by 93
Acuff, H. B., Sinnamon, M. J., Fingleton, B., Boone, B. E., Levy, S., Chen, X., Pozzi, A., Carbone, D. P., Schwartz, D. R., Moin, K., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4279 · Cited by 92
Ohtsuka, T., Shiomi, T., Shimoda, M., Kodama, T., Amour, A., Murphy, G., Ohuchi, E., Kobayashi, K., & Okada, Y. (2005) · International Journal of Cancer · doi:10.1002/ijc.21324 · Cited by 90
Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer
Langenski�ld, M., Holmdahl, L., Falk, P., & Ivarsson, M. (2004) · International Journal of Colorectal Disease · doi:10.1007/s00384-004-0667-4 · Cited by 88
Miyake, H., Muramaki, M., Kurahashi, T., Takenaka, A., & Fujisawa, M. (2008) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.08.001 · Cited by 87
The plasminogen activator and matrix metalloproteinase systems in colorectal cancer
Baker, E. A., & Leaper, D. J. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00065-0 · Cited by 86
A Randomized Phase II Feasibility Trial of BMS-275291 in Patients with Early Stage Breast Cancer
Miller, K. D., Saphner, T. J., Waterhouse, D. M., Chen, T., Rush-Taylor, A., Sparano, J. A., Wolff, A. C., Cobleigh, M., Galbraith, S. M., & Sledge, G. W. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0968 · Cited by 83
Jäälinoja, J., Herva, R., Korpela, M., Höyhtyä, M., & Turpeenniemi-Hujanen, T. (2000) · Journal of Neuro-Oncology · doi:10.1023/a:1006421112839 · Cited by 82
Betz, M., Huxley, P., Davies, S. J., Mushtaq, Y., Pieper, M. P., Tschesche, H., Bode, W., & Gomis‐Rüth, F. X. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00356.x · Cited by 81
Périgny, M., Bairati, I., Harvey, I., Beauchemin, M., Harel, F., Plante, M., & Têtu, B. (2008) · American Journal of Clinical Pathology · doi:10.1309/49la9xcbgwj8f2km · Cited by 80
Fritzsche, F. R., Jung, M., Tölle, A., Wild, P. J., Hartmann, A., Wassermann, K., Rabien, A., Lein, M., Dietel, M., Pilarsky, C. P., et al. (2007) · European Urology · doi:10.1016/j.eururo.2007.11.034 · Cited by 79
Kuhlmann, K. F. D., van Till, J. W. O., Boermeester, M. A., de Reuver, P. R., Tzvetanova, I. D., Offerhaus, G. J. A., ten Kate, F. J. W., Busch, O. R., van Gulik, T. M., Gouma, D. J., et al. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0779 · Cited by 78
Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer
Sillanpää, S. M., Anttila, M., Voutilainen, K., Ropponen, K. M., Turpeenniemi-Hujanen, T. M., Puistola, U., Tammi, R., Tammi, M., Sironen, R. K., Saarikoski, S., et al. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.09.004 · Cited by 77
Baciu, P. C., Suleiman, E. A., Deryugina, E. I., & Strongin, A. Y. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(03)00387-2 · Cited by 75
Kleifeld, O., Kotra, L. P., Gervasi, D. C., Brown, S., Bernardo, M. M., Fridman, R. A., Mobashery, S., & Sagi, I. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011604200 · Cited by 74
Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors
Callier‐Dublanchet, A., Ducrot, P., Andrianjara, C. R., O’Gara, M., Morales, R., Compère, D., Denis, A., Blais, S., Cluzeau, P., Courté, K., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.05.079 · Cited by 68
Matrix Metalloproteinase-1 Promoter Polymorphism and Lung Cancer Risk
Su, L., Zhou, W., Park, S., Wain, J. C., Lynch, T. J., Liu, G., & Christiani, D. C. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0482 · Cited by 65
Liu, X., Fridman, J. S., Wang, Q., Caulder, E., Yang, G., Covington, M. B., Liu, C., Marando, C. A., Zhuo, J., Li, Y., et al. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.6.2707 · Cited by 61
Sauer, C. G., Kappeler, A., Sp�th, M., Kaden, J., Michel, M., Mayer, D., Bleyl, U., & Grobholz, R. (2004) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-004-1016-2 · Cited by 58
Trudel, D., Fradet, Y., Meyer, F., Harel, F., & Têtu, B. (2008) · Human Pathology · doi:10.1016/j.humpath.2007.09.021 · Cited by 56
Matrix-degrading metalloproteinases in tumor progression.
Matrisian, L. M., Wright, J. R., Newell, K. J., & Witty, J. P. (1994) · PubMed · Cited by 54
ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis
Fritzsche, F. R., Jung, M., Xu, C., Rabien, A., Schicktanz, H., Stephan, C., Dietel, M., Jung, K., & Kristiansen, G. (2006) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-006-0315-1 · Cited by 45
Design, Synthesis, and Evaluation of a Mechanism-Based Inhibitor for Gelatinase A
Ikejiri, M., Bernardo, M. M., Meroueh, S. O., Brown, S., Chang, M., Fridman, R. A., & Mobashery, S. (2005) · The Journal of Organic Chemistry · doi:10.1021/jo050339+ · Cited by 41
Smith, E. R., Manfredi, M. A., Scott, R. M., Black, P. M., & Moses, M. A. (2007) · Neurosurgery · doi:10.1227/01.neu.0000255464.37634.3c · Cited by 29
Self-citationZucker, S., & Cao, J. P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0774 · Cited by 26
Activation of ADAM 12 protease by copper
Loechel, F., & Wewer, U. M. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02873-3 · Cited by 16
Cited by
Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting
Gialeli, C., Theocharis, A. D., & Karamanos, N. K. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07919.x · Cited by 1,607
A proteomic atlas of senescence-associated secretomes for aging biomarker development
Basisty, N., Kale, A., Jeon, O. H., Kuehnemann, C., Payne, T., Rao, C., Holtz, A., Shah, S., Sharma, V., Ferrucci, L., et al. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000599 · Cited by 1,348
Multistage nanoparticle delivery system for deep penetration into tumor tissue
Wong, C., Stylianopoulos, T., Cui, J., Martin, J., Chauhan, V. P., Jiang, W., Popović, Z., Jain, R. K., Bawendi, M. G., & Fukumura, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018382108 · Cited by 1,062
Iron Oxide Based Nanoparticles for Multimodal Imaging and Magnetoresponsive Therapy
Lee, N., Yoo, D., Ling, D., Cho, M. H., Hyeon, T., & Cheon, J. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00112 · Cited by 1,005
Is there new hope for therapeutic matrix metalloproteinase inhibition?
Vandenbroucke, R. E., & Libert, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4390 · Cited by 832
Metadata
- Authors
- Roy, R., Yang, J., & Moses, M. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-11-01
- Volume
- 27
- Issue
- 31
- Pages
- 5287-5297
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2050834003
- Cited by
- 854
- References
- 128
- FWCI
- 18.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.